Biotheus Inc. is a clinical-stage biotech company focused on the discovery and development of innovative biologics, particularly in the fields of oncology and inflammatory diseases. The company has developed a range of bispecific antibodies, such as PM1080, which targets both EGFR and c-MET, and PM8002, which blocks PD-L1 and VEGF pathways. These bispecific antibodies are designed to enhance therapeutic efficacy by specifically targeting tumor antigens and reducing off-target effects, thereby improving safety profiles. Biotheus employs advanced technologies for antibody discovery, engineering, and screening, which support their robust pipeline of products currently in various stages of clinical development.

In addition to bispecific antibodies, Biotheus is also exploring combination therapies and innovative immunotherapies to address unmet medical needs in cancer treatment. Their pipeline includes next-generation checkpoint inhibitors and antagonists targeting pathways like CD73 and CD39, which are crucial for modulating the tumor microenvironment and enhancing anti-tumor immune responses. The company’s commitment to leveraging its proprietary technology platforms aims to expedite the development of effective treatments for patients suffering from cancer and autoimmune diseases, ultimately striving to improve patient outcomes and quality of life.

China

Biotheus (普米斯生物技术) aims to discover and develop effective therapeutic biologics for patients with cancer and inflammatory disease. We believe in creative scientific and industrial/academic collaborations in order to reach this common goal.

Biotheus

Company Details